Antiarrhythmic Effects and Mechanisms of Sodium-glucose Cotransporter 2 Inhibitors: A Mini Review

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2022 Aug 25

PMID 36003915

Authors

Jinchun Wu

Yanmin Liu

Xiaojuan Wei

Xiaofei Zhang

Yi Ye

Wei Li

Xiaoling Su

Affiliations

Soon will be listed here.

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a new type of oral hypoglycaemic agent with good cardiovascular protective effects. There are several lines of clinical evidence suggest that SGLT2i can significantly reduce the risks of heart failure, cardiovascular death, and delay the progression of chronic kidney disease. In addition, recent basic and clinical studies have also reported that SGLT2i also has good anti-arrhythmic effects. However, the exact mechanism is poorly understood. The aim of this review is to summarize recent clinical findings, studies of laboratory animals, and related study about this aspect of the antiarrhythmic effects of SGLT2i, to further explore its underlying mechanisms, safety, and prospects for clinical applications of it.

Citing Articles

The Role of Sodium Glucose Co-Transporter 2 Inhibitors in Atrial Fibrillation: A Comprehensive Review.

Stachteas P, Nasoufidou A, Karagiannidis E, Patoulias D, Karakasis P, Alexiou S J Clin Med. 2024; 13(18).

PMID: 39336895 PMC: 11431971. DOI: 10.3390/jcm13185408.

The effects of empagliflozin on ventricular arrhythmias in heart failure patients with an implantable cardioverter-defibrillator: a double-blind randomized controlled trial.

Abedi F, Mohammadpour A, Ghavami V, Heidari-Bakavoli A, Jomezadeh V, Tayyebi M Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(12):10191-10201.

PMID: 39002088 DOI: 10.1007/s00210-024-03224-2.

Impact of SGLT2 Inhibitors on Atrial Fibrillation Recurrence after Catheter Ablation in Type 2 Diabetes Mellitus: A Meta-Analysis of Reconstructed Kaplan-Meier Curves with Trial Sequential Analysis.

Soliman Y, Abuelazm M, Amer B, Hukamdad M, Ellabban M, Hendi N Am J Cardiovasc Drugs. 2024; 24(5):629-640.

PMID: 38963527 PMC: 11344729. DOI: 10.1007/s40256-024-00661-5.

References

Ye Y, Zhao C, Liang J, Yang Y, Yu M, Qu X . Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk. Front Pharmacol. 2019; 9:1517. PMC: 6331441. DOI: 10.3389/fphar.2018.01517. View

Heerspink H, Perco P, Mulder S, Leierer J, Hansen M, Heinzel A . Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019; 62(7):1154-1166. PMC: 6560022. DOI: 10.1007/s00125-019-4859-4. View

Li D, Liu Y, Hidru T, Yang X, Wang Y, Chen C . Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials. Front Endocrinol (Lausanne). 2021; 12:619586. PMC: 8018283. DOI: 10.3389/fendo.2021.619586. View

Curtain J, Docherty K, Jhund P, Petrie M, Inzucchi S, Kober L . Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J. 2021; 42(36):3727-3738. PMC: 8455345. DOI: 10.1093/eurheartj/ehab560. View

Hamouda N, Sydorenko V, Qureshi M, Alkaabi J, Oz M, Howarth F . Dapagliflozin reduces the amplitude of shortening and Ca(2+) transient in ventricular myocytes from streptozotocin-induced diabetic rats. Mol Cell Biochem. 2014; 400(1-2):57-68. DOI: 10.1007/s11010-014-2262-5. View

Azam M, Chakraborty P, Si D, Du B, Masse S, Lai P . Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia. Life Sci. 2021; 276:119440. DOI: 10.1016/j.lfs.2021.119440. View

Shattock M, Ottolia M, Bers D, Blaustein M, Boguslavskyi A, Bossuyt J . Na+/Ca2+ exchange and Na+/K+-ATPase in the heart. J Physiol. 2015; 593(6):1361-82. PMC: 4376416. DOI: 10.1113/jphysiol.2014.282319. View

Mustroph J, Wagemann O, Lucht C, Trum M, Hammer K, Sag C . Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes. ESC Heart Fail. 2018; 5(4):642-648. PMC: 6073019. DOI: 10.1002/ehf2.12336. View

Filippatos T, Liontos A, Papakitsou I, Elisaf M . SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. Postgrad Med. 2019; 131(2):82-88. DOI: 10.1080/00325481.2019.1581971. View

10.

Chilton R, Tikkanen I, Cannon C, Crowe S, Woerle H, Broedl U . Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015; 17(12):1180-93. PMC: 5057299. DOI: 10.1111/dom.12572. View

11.

Ni L, Yuan C, Chen G, Zhang C, Wu X . SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol. 2020; 19(1):98. PMC: 7320582. DOI: 10.1186/s12933-020-01071-y. View

12.

Fedak P, Verma S, Weisel R, Skrtic M, Li R . Cardiac remodeling and failure: from molecules to man (Part III). Cardiovasc Pathol. 2005; 14(3):109-19. DOI: 10.1016/j.carpath.2005.03.004. View

13.

Kho C, Lee A, Hajjar R . Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy. Nat Rev Cardiol. 2012; 9(12):717-33. PMC: 3651893. DOI: 10.1038/nrcardio.2012.145. View

14.

Trum M, Riechel J, Wagner S . Cardioprotection by SGLT2 Inhibitors-Does It All Come Down to Na?. Int J Mol Sci. 2021; 22(15). PMC: 8347698. DOI: 10.3390/ijms22157976. View

15.

Mirabelli M, Chiefari E, Caroleo P, Vero R, Brunetti F, Corigliano D . Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus. J Diabetes Res. 2019; 2019:3971060. PMC: 6875368. DOI: 10.1155/2019/3971060. View

16.

Rochette L, Zeller M, Cottin Y, Vergely C . Diabetes, oxidative stress and therapeutic strategies. Biochim Biophys Acta. 2014; 1840(9):2709-29. DOI: 10.1016/j.bbagen.2014.05.017. View

17.

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

18.

Rijzewijk L, van der Meer R, Smit J, Diamant M, Bax J, Hammer S . Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol. 2008; 52(22):1793-9. DOI: 10.1016/j.jacc.2008.07.062. View

19.

Xie W, Santulli G, Reiken S, Yuan Q, Osborne B, Chen B . Mitochondrial oxidative stress promotes atrial fibrillation. Sci Rep. 2015; 5:11427. PMC: 4501003. DOI: 10.1038/srep11427. View

20.

Light P . Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure. Eur Heart J. 2021; 42(36):3739-3740. PMC: 8455342. DOI: 10.1093/eurheartj/ehab563. View